Phase 2 Readout~quarter

Phase 2 Readout: kt-621

Drug
kt-621
Indication
moderate to severe atopic dermatitis

Other upcoming events for KYMR

Phase 2 ReadoutPhase 2 Readout: kt-621

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar